Evotec SE
Company Profile
Business description
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Contact
Essener Bogen 7
Manfred Eigen Campus
Hamburg22419
DEUT: +49 40560810
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
4,766
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,586.70 | 15.30 | 0.18% |
CAC 40 | 7,734.40 | 130.04 | -1.65% |
DAX 40 | 23,629.58 | 369.59 | -1.54% |
Dow JONES (US) | 41,603.07 | 256.02 | -0.61% |
FTSE 100 | 8,717.97 | 21.29 | -0.24% |
HKSE | 23,601.26 | 56.95 | 0.24% |
NASDAQ | 18,737.21 | 188.53 | -1.00% |
Nikkei 225 | 37,160.47 | 174.60 | 0.47% |
NZX 50 Index | 12,596.50 | 65.75 | -0.52% |
S&P 500 | 5,802.83 | 39.18 | -0.67% |
S&P/ASX 200 | 8,360.90 | 12.20 | 0.15% |
SSE Composite Index | 3,348.37 | 31.82 | -0.94% |